Nom du produit:tert-butyl (2-hydroxyethyl)(isopropyl)carbamate
IUPAC Name:tert-butyl N-(2-hydroxyethyl)-N-(propan-2-yl)carbamate
- CAS：610309-73-4
- Formule moléculaire：C10H21NO3
- Pureté：95%+
- Numéro de catalogue：CM1020214
- Poids moléculaire：203.28
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:610309-73-4
- Formule moléculaire:C10H21NO3
- Point de fusion:-
- Code SMILES:CC(C)N(CCO)C(=O)OC(C)(C)C
- Densité:
- Numéro de catalogue:CM1020214
- Poids moléculaire:203.28
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Aliphatic Chain Compounds
- Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.
Column Infos
- XRD-0394
- XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.
XRD-0394, is a first-in-class dual inhibitor of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Initial development efforts are focused on evaluating XRD-0394’s ability to enhance radiation therapy when used in combination. In parallel, the company is exploring the potential benefits of using XRad’s dual kinase inhibitors in combination with targeted radionuclides, immune checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors and antibody drug conjugates.
Recherche 
+86 21 5895 0110 
